- US-listed companies
- Amphastar Pharmaceuticals, Inc.
- Income statement
Amphastar Pharmaceuticals, Inc.【AMPH】Income statement
Market cap
$1.3B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 210 | 252 | 255 | 240 | 295 | 322 | 350 | 438 | 499 | 644 | 732 |
| Revenue growth (%) | - | ||||||||||
| Cost of revenue | 159 | 174 | 151 | 149 | 188 | 190 | 207 | 238 | 250 | 293 | 358 |
| Gross profit | 51 | 77 | 104 | 91 | 107 | 132 | 143 | 200 | 249 | 351 | 374 |
| Gross margin (%) | |||||||||||
| Research & development | 28 | 37 | 41 | 43 | 58 | 69 | 67 | 61 | 75 | 74 | 74 |
| Operating margin (%) | |||||||||||
| Operating income | -18 | -7 | 16 | -1 | -9 | -0 | 11 | 70 | 107 | 197 | 205 |
| Operating expenses | 69 | 84 | 88 | 92 | 116 | 132 | 132 | 130 | 141 | 154 | 168 |
| Income before tax | -18 | -10 | 15 | 2 | -10 | 60 | 5 | 84 | 116 | 171 | 190 |
| Pretax margin (%) | -8.6 | -4.1 | 5.9 | 0.7 | -3.4 | 18.7 | 1.3 | 19.2 | 23.3 | 26.6 | 25.9 |
| Provision for income taxes | -7 | -8 | 4 | -3 | -3 | 14 | 4 | 21 | 23 | 32 | 30 |
| Effective tax rate (%) | |||||||||||
| Net income | -11 | -3 | 11 | 5 | -6 | 49 | 1 | 63 | 91 | 138 | 160 |
| Net income margin (%) | |||||||||||
| Earnings per share | -0.25 | -0.06 | 0.23 | 0.1 | -0.12 | 1.04 | 0.03 | 1.3 | 1.88 | 2.85 | 3.29 |
| Diluted EPS | -0.25 | -0.06 | 0.22 | 0.09 | -0.12 | 0.98 | 0.03 | 1.25 | 1.74 | 2.6 | 3.06 |